We hypothesised that PPAR-α and -γ agonists (fibrates and glitazones) would be associated with a reduced risk of developing brain tumours compared with other treatments for hyperlipidaemia and diabetes using the UK Clinical Practice Research Datalink (CPRD), a very large, population-based, primary care database. Here, PPARA is linked to hyperlipidemia.